
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Click the title above to open the Pharmaceutical Executive September 2017 issue in an interactive PDF format.
about 9 years ago
Pharm Exec's 16th Annual Industry Auditabout 9 years ago
The Supply Chain: What Price Patient Centricity?about 9 years ago
Drug Serialization for DSCSA Compliance Benefits Everyoneabout 9 years ago
Pharm Exec's 16th Annual Industry Audit (Overview)about 9 years ago
You Are Pharmaabout 9 years ago
Leading With Patients in Mind: Cynthia Schwalmabout 9 years ago
FDA, Industry Prepare for New User Fee Initiativesabout 9 years ago
Data Inflection Pointabout 9 years ago
UK Unveils Post-Brexit Life Sciences Strategyabout 9 years ago
Seizing the Opportunity in STEM





